REGENXBIO Doses First Patient in NAAVIGATE Gene Trial
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
ROCKVILLE, Md., June 29, 2026 REGENXBIO Inc. has reached a major milestone in the advancement of gene therapy for...
PHILADELPHIA, May 14, 2026 GEMMA Biotherapeutics (GEMMABio) unveiled its new Duchenne muscular dystrophy (DMD) gene therapy program and presented...
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Encoded Therapeutics announced new preclinical findings at the 2026 American Society of...
DURHAM, N.C., May 11, 2026 AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary...
RESEARCH TRIANGLE PARK, N.C. – May 4, 2026 Opus Genetics Inc. has announced that its investigational gene therapy OPGx-LCA5...
SOUTH SAN FRANCISCO, Calif., April 27, 2026 Encoded Therapeutics announced its participation in the 29th Annual Meeting of the...
Research Triangle Park, N.C. | January 27, 2026 — Opus Genetics, Inc., a clinical-stage biopharmaceutical company focused on inherited...
